ReviewBiomedicines2021
Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma.Frontiers in immunology · 2026Article
- Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics.Biomedicines · 2025Review
- Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma.Frontiers in allergy · 2025Article
- The effect of COVID-19 on patients recieving omalizumab treatment.Revue francaise d'allergologie (2009) · 2023Article
- Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023Review
- Sirtuin 1 Expression Enhances the Inflammatory Response in Allergic Rhinitis Combined with Asthma.Archives of Razi Institute · 2022Article
- SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.The journal of allergy and clinical immunology. In practice · 2022Article
- COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.Allergy · 2022Article
- Asthma and COVID-19 Associations: Focus on IgE-Related Immune Pathology.Life (Basel, Switzerland) · 2022Review
- Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile.Frontiers in pediatrics · 2022Review
- Allergic patients during the COVID-19 pandemic-Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey.Clinical and translational allergy · 2022Article
- Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.Journal of inflammation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral respiratory infections are recognized risk factors for the loss of control of allergic asthma and the induction of exacerbations, both in adults and children. Severe asthma is more susceptible to virus-induced asthma exacerbations, especially in the presence of high IgE levels. In the course of immune responses to viruses, an initial activation of innate immunity typically occurs and the production of type I and III interferons is essential in the control of viral spread. However, the Th2 inflammatory environment still appears to be protective against viral infections in general and in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections as well. As for now, literature data, although extremely limited and preliminary, show that severe asthma patients treated with biologics don't have an increased risk of SARS-CoV-2 infection or progression to severe forms compared to the non-asthmatic population. Omalizumab, an anti-IgE monoclonal antibody, exerts a profound cellular effect, which can stabilize the effector cells, and is becoming much more efficient from the point of view of innate immunity in contrasting respiratory viral infections. In addition to the antiviral effect, clinical efficacy and safety of this biological allow a great improvement in the management of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.